Although the significance of ALK ligand mutation requires further investigation, we suggest that children with NB lacking ALK mutation, but with ALK activation and/or mutations in ALK ligands, are considered for ALK-inhibiting targeted therapy. This evidence concerns the gene ALK and neuroblastoma.